

**Glaucoma Update 2025: Point and Counterpoint, Novel and Interdisciplinary Glaucoma Management Considerations**

**Saturday, February 1, 2025**

*Wills Eye Auditorium*

**Conference Description:**

[Click Here to Register for the Livestream](https://attendee.gotowebinar.com/register/6773017356350373216)

We will discuss latest advances in the management of glaucoma and evidence for emerging therapies and screening modalities. Both point/counter-point and didactic formats will be utilized to illustrate current trends in the management of complex and routine glaucoma patients, taking into account novel techniques as well as interdisciplinary glaucoma management.

**At the conclusion of the course, participants should be able to:**

1 Appropriately refer glaucoma patients in need of advanced treatment

2 Manage or refer patients with complex ocular pathology

3 Order and interpret glaucoma diagnostic tests

4 Evaluate and implement when appropriate new glaucoma surgical procedures

5 Improve practitioner self-care

**Accreditation Statement:**

The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**Credit Statement Designation:**

Wills Eye Hospital designates this Live Activity for a maximum of 3.50 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosure Statement:**

It is the policy of Wills Eye Hospital that the information presented at Wills Eye Hospital's CME activities will be commercially unbiased and based on scientific and clinical evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that planners and speakers have disclosed about financial relationships they have with commercial entities that produce, market, re-sell, or distribute health care goods or services consumed by, or used on, patients. All relevant financial relationships have been mitigated.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Ralph C. Eagle Jr., MD | Other Planning Committee Member | Nothing to disclose - 10/10/2024 |
| Marisa Schoen, MD | Faculty | Nothing to disclose - 03/05/2024 |
| Meera Sivalingam, MD | Faculty | Nothing to disclose - 01/06/2025 |
| Reza Razeghinejad, MD | Faculty | Grant or research support-Olleyes|Grant or research support-Equinox (Relationship has ended) - 01/02/2025 |
| Cindy Zheng , MD | Faculty | Nothing to disclose - 12/16/2024 |
| Jesse Richman, MD | Faculty | Consulting Fee-Alcon|Royalties or Patent Beneficiary-Visionology|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Visionology (Relationship has ended)|Paid consultant-Allergan (Relationship has ended) - 01/02/2025 |
| Lindsay Machen, MD | Faculty | Other: Investor-Elios Vision (Relationship has ended) - 12/19/2024 |
| Jason Flamendorf, MD | Faculty | Nothing to disclose - 01/02/2025 |
| Alice Williams, MD | Faculty | Nothing to disclose - 10/05/2024 |
| Lauren Hock, MD | Faculty | Nothing to disclose - 12/19/2024 |
| Tina Xia, MD | Faculty | Grant or research support-AbbVie - 01/02/2025 |
| Ping Huang, MD, PhD | Faculty | Nothing to disclose - 12/16/2024 |
| Dilru C Amarasekera, MD | Faculty, Peer Reviewer, Planner | Nothing to disclose - 12/16/2024 |
| Joel S Schuman , MD | Faculty | Consulting Fee-Zeiss|Advisor-Opticient|Advisor-AEYE Health|Consulting Fee-Alcon|Consulting Fee-Broadwing|Advisor-Ocugenix|Consulting Fee-Perfuse|Grant or research support-Perfuse (Relationship has ended)|Consulting Fee-Ocular Therpeutics|Public Corp Stock-Ocular Therapeutix|Consulting Fee-Dompé |Grant or research support-Topcon - 12/06/2024 |
| Danijel J Pericic, MD | Faculty | Nothing to disclose - 11/12/2024 |
| Michael Pro, MD | Faculty, Planner | Consulting Fee-Alcon|Consulting Fee-New World Medical - 01/06/2025 |

